Tuesday, July 23, 2024

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine

FDA Licenses Merck’s Capvaxive Pneumococcal Vaccine

On June 17, 2024, the U.S. Food and Drug Administration (FDA) licensed Merck & Company, Inc.’s new pneumococcal conjugate vaccine Capvaxive (formerly V116) for adults 18 years of age and older. The vaccine is designed to protect against 21 types of the bacteria causing pneumococcal disease, which can lead to severe infection in the lungs […]

Search in Site

To search in site, type your keyword and hit enter

Search